DÄ internationalArchiveReferences

Original article

The Efficacy and Evidence-Based Use of Biologics in Children and Adolescents

Dtsch Arztebl Int 2019; 116: 703-10. DOI: 10.3238/arztebl.2019.0703

Niehues, T; Özgür, T T

1.Benchimol EI, Fortinsky KJ, Gozdyra P, Van den Heuvel M, Van Limbergen J, Griffiths AM: Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis 2011; 17: 423–39 CrossRef MEDLINE
2.Robert Koch-Institut: Asthma bronchiale. Faktenblatt zu KiGGS Welle 1: Studie zur Gesundheit von Kindern und Jugendlichen in Deutschland – Erste Folgebefragung 2009 – 2012. RKI, Berlin. Robert Koch-Institut, Gesundheitsberichterstattung des Bundes 2014.
3.Thomschke S, Schulz M, Bätzing J: Epidemiologie der juvenilen idiopathischen Arthritis (JIA) in der ambulanten Versorgung – eine Analyse anhand bundesweiter vertragsärztlicher Abrechnungsdaten der Jahre 2009 bis 2015. Versorgungsatlas 2018.
4.Boyman O, Comte D, Spertini F: Adverse reactions to biologic agents and their medical management. Nat Rev Rheumatol 2014; 10: 612–27 CrossRef MEDLINE
5.Davis BP, Ballas ZK: Biologic response modifiers: Indications, implications, and insights. J Allergy Clin Immunol 2017; 139: 1445–56 CrossRef MEDLINE
6.Feyen O, Lueking A, Kowald A, et al.: Off-target activity of TNF-alpha inhibitors characterized by protein biochips. Anal Bioanal Chem 2008; 391: 1713–20. CrossRef MEDLINE
7.Oude Munnink TH, Henstra MJ, Segerink LI, Movig KL, Brummelhuis-Visser P: Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: Translating TNF-alpha experience to oncology. Clin Pharmacol Ther 2016; 99: 419–31 CrossRef MEDLINE
8.Malik P, Edginton A: Pediatric physiology in relation to the pharmacokinetics of monoclonal antibodies. Expert Opin Drug Metab Toxicol 2018; 14: 585–99 CrossRef MEDLINE
9.Edlund H, Melin J, Parra-Guillen ZP, Kloft C: Pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of monoclonal antibodies in children. Clin Pharmacokinet 2015; 54: 35–80 CrossRef MEDLINE
10.NVL-Programm von BÄK, AWMF: Nationale Versorgungs-Leitlinie Asthma. www.awmf.org/leitlinien/detail/ll/nvl-002.html (last accessed on 12 August 2019)
11.Teach SJ, Gill MA, Togias A, et al.: Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol 2015; 136: 1476–85 CrossRef MEDLINE PubMed Central
12.Busse WW, Morgan WJ, Gergen PJ, et al.: Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 2011; 364: 1005–15 CrossRef MEDLINE PubMed Central
13.Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF: Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol 2009; 124: 1210–6 CrossRef MEDLINE
14.Milgrom H, Berger W, Nayak A, et al.: Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001; 108: E36 CrossRef MEDLINE
15.arznei-telegramm: Warnung vor Anaphylaxie durch Asthmamittel Omalizumab (Xolair) www.arznei-telegramm.de/html/2007_07/0707071_02.html (last accessed on 12 August 2019)
16. Deutsche Diabetes Gesellschaft: S2k-Leitlinie Therapie der Psoriasis bei Kindern und Jugendlichen www.awmf.org/leitlinien/detail/ll/013–094.html (last accessed on 12 August 2019).
17.de Carvalho AV, Duquia RP, Horta BL, Bonamigo RR: Efficacy of immunobiologic and small molecule inhibitor drugs for psoriasis: a systematic review and meta-analysis of randomized clinical trials. Drugs R D 2017; 17: 29–51 CrossRef MEDLINE PubMed Central
18.Sbidian E, Chaimani A, Garcia-Doval I, et al.: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev 2017; 12: CD011535 CrossRef MEDLINE PubMed Central
19.Ramanan AV, Whitworth P, Baildam EM: Use of methotrexate in juvenile idiopathic arthritis. Arch Dis Child 2003; 88: 197–200 CrossRef MEDLINE PubMed Central
20.Papp K, Thaci D, Marcoux D, et al.: Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial. Lancet 2017; 390: 40–9 CrossRef
21.Paller AS, Siegfried EC, Langley RG, et al.: Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 2008; 358: 241–51 CrossRef MEDLINE
22.Landells I, Marano C, Hsu MC, et al.: Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol 2015; 73: 594–603 CrossRef MEDLINE
23.Dueckers G, Guellac N, Arbogast M, et al.: Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis. Clin Immunol 2012; 142: 176–93 CrossRef MEDLINE
24.Ruperto N, Lovell DJ, Cuttica R, et al.: A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2007; 56: 3096–106 CrossRef MEDLINE
25.Wallace CA, Giannini EH, Spalding SJ, et al.: Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum 2012; 64: 2012–21 CrossRef MEDLINE PubMed Central
26.Tynjälä P, Vahasalo P, Tarkiainen M, et al.: Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial. Ann Rheum Dis 2011; 70: 1605–12 CrossRef MEDLINE
27.Hissink Müller PC, Brinkman DM, Schonenberg D, et al.: A comparison of three treatment strategies in recent onset non-systemic juvenile idiopathic arthritis: initial 3-months results of the BeSt for Kids-study. Pediatr Rheumatol Online J 2017; 15: 11 CrossRef MEDLINE PubMed Central
28.Burgos-Vargas R, Tse SM, Horneff G, et al.: A randomized, double-blind, placebo-controlled multicenter study of adalimumab in pediatric patients with enthesitis-related arthritis. Arthritis Care Res (Hoboken) 2015; 67: 1503–12 CrossRef MEDLINE PubMed Central
29.Horneff G, Fitter S, Foeldvari I, et al.: Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement. Arthritis Res Ther 2012; 14: R230 CrossRef MEDLINE PubMed Central
30.Quartier P, Allantaz F, Cimaz R, et al.: A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2011; 70: 747–54 CrossRef MEDLINE PubMed Central
31.Ruperto N, Quartier P, Wulffraat N, et al.: A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum 2012; 64: 557–67 CrossRef MEDLINE
32.de Benedetti F, Brunner HI, Ruperto N, et al.: Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012; 367: 2385–95 CrossRef MEDLINE
33.Yokota S, Imagawa T, Mori M, et al.: Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008; 371: 998–1006 CrossRef
34.Horneff G, Foeldvari I, Minden K, et al.: Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study. Arthritis Rheumatol 2015; 67: 2240–9 CrossRef MEDLINE
35.Ruperto N, Lovell DJ, Quartier P, et al.: Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008; 372: 383–91 CrossRef
36.Lovell DJ, Ruperto N, Goodman S, et al.: Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008; 359: 810–20 CrossRef MEDLINE
37.Lovell DJ, Giannini EH, Reiff A, et al.: Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000; 342: 763–9 CrossRef MEDLINE
38.Brunner HI, Ruperto N, Zuber Z, et al.: Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis 2015; 74: 1110–7 CrossRef MEDLINE PubMed Central
39.Brunner HI, Rider LG, Kingsbury DJ, et al.: Pediatric Rheumatology Collaborative Study Group – over four decades of pivotal clinical drug research in pediatric rheumatology. Pediatr Rheumatol Online J 2018; 16: 45 CrossRef MEDLINE PubMed Central
40.Deutsche Ophthalmologische Gesellschaft: Diagnostik und antientzündliche Therapie der Uveitis bei juveniler idiopathischer Arthritis. www.awmf.org/leitlinien/detail/ll/045–012.html (last accessed on 13 August 2019).
e1.Ramanan AV, Dick AD, Jones AP, et al.: Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis. N Engl J Med 2017; 376: 1637–46 CrossRef MEDLINE
e2.Smith JA, Thompson DJ, Whitcup SM, et al.: A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 2005; 53: 18–23 CrossRef MEDLINE
e3.Swart J, Giancane G, Horneff G, et al.: Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries. Arthritis Res Ther 2018; 20: 285 CrossRef MEDLINE PubMed Central
e4.Diak P, Siegel J, La Grenade L, Choi L, Lemery S, McMahon A: Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum 2010; 62: 2517–24 CrossRef MEDLINE
e5.Simard JF, Neovius M, Hagelberg S, Askling J: Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study. Arthritis Rheum 2010; 62: 3776–82 CrossRef MEDLINE
e6.Kemanetzoglou E, Andreadou E: CNS demyelination with TNF-alpha blockers. Curr Neurol Neurosci Rep 2017; 17: 36 CrossRef MEDLINE
e7.Kakkassery V, Mergler S, Pleyer U: Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment. Curr Eye Res 2010; 35: 751–6 PubMed Central CrossRef MEDLINE
e8.Barthel D, Ganser G, Kuester RM, et al.: Inflammatory bowel disease in juvenile idiopathic arthritis patients treated with biologics. J Rheumatol 2015; 42: 2160–5 CrossRef MEDLINE
e9.Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten: S3-Leitlinie 021/004: Diagnostik und Therapie des Morbus Crohn www.awmf.org/leitlinien/detail/ll/021–004.html (last accessed on 2 September 2019).
e10.Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten: S3 Leitlinie 021–009 Diagnostik und Therapie der Colitis ulcerosa. www.kompetenznetz-darmerkrankungen.de/files/cto_layout/img/Diagnostik-und-Therapie-der-Colitis-ulcerosa.pdf (last accessed on on 2 September 2019).
e11.Cholapranee A, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, Ananthakrishnan AN: Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn‘s disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther 2017; 45: 1291–302 CrossRef MEDLINE PubMed Central
e12.Däbritz J, Gerner P, Enninger A, Claßen M, Radke M: Inflammatory bowel disease in childhood and adolescence—diagnosis and treatment. Dtsch Arztebl Int 2017; 114: 331–8 CrossRef MEDLINE PubMed Central
e13.Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M: Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007; 44: 265–7 CrossRef MEDLINE
e14.Ethical considerations for clinical trials on medicinal products conducted with minors. Recommendations of the expert group on clinical trials for the implementation of Regulation (EU) No 536/2014 on clinical trials on medicinal products for human use. www.ec.europa. eu/health/sites/health/files/files/eudralex/vol-10/2017_09_18_ethical_ consid_ct_with_minors.pdf (last accessed on 12.-August 2019).
e15.Windeler J, Lauterberg J, Wieseler B, Sauerland S: Patientenregister für die Nutzenbewertung: Kein Ersatz für randomisierte Studien. Dtsch Arztebl 2017; 114(16): A-783–6.
e16.Gesellschaft für Kinder- und Jugendrheumatologie: Forschungsprojekte in der Kinderrheumatologie. www.gkjr.de/forschungsprojekte/forschungsprojekte-in-der-kinderrheumatologie/ (last accessed on 12 August 2019).
e17.UN-Kinderrechtskonvention: Übereinkommen über die Rechte des Kindes (Convention on the Rights of the Child, CRC). www.kinderrechtskonvention.info/ (last accessed on 12 August 2019).
e18.Pocock SJ: The pros and cons of noninferiority trials. Fundam Clin Pharmacol 2003; 17: 483–90 CrossRef
e19.Feldman B, Wang E, Willan A, Szalai JP: The randomized placebo-phase design for clinical trials. J Clin Epidemiol 2001; 54: 550–7 CrossRef
e20.Demirkaya E, Lanni S, Bovis F, et al.: A meta-analysis to estimate the placebo effect in randomized controlled trials in juvenile idiopathic arthritis. Arthritis Rheumatol 2016; 68: 1540–50 CrossRef MEDLINE
e21.Abrahamyan L, Feldman BM, Tomlinson G, et al.: Alternative designs for clinical trials in rare diseases. Am J Med Genet C Semin Med Genet 2016; 172: 313–31 CrossRef MEDLINE
e22.Lehman TJ: Are withdrawal trials in paediatric rheumatic disease helpful? Lancet 2008; 372: 348–50 CrossRef
e23. Boyman O, Comte D, Spertini F: Adverse reactions to biologic agents and their medical management. Nat Rev Rheumatol 2014; 10: 612–27 CrossRef MEDLINE
e24. Davis BP, Ballas ZK: Biologic response modifiers: Indications, implications, and insights. J Allergy Clin Immunol 2017; 139: 1445–56 CrossRef MEDLINE
e25. Picard M, Galvao VR: Current knowledge and management of hypersensitivity reactions to monoclonal antibodies. J Allergy Clin Immunol Pract 2017; 5: 600–9 CrossRef MEDLINE
e26. Corren J, Kavati A, Ortiz B, et al.: Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma: a systematic literature review. Allergy Asthma Proc 2017; 38: 250–63 CrossRef MEDLINE
e27. Ehmann LM, Tillack-Schreiber C, Brand S, Wollenberg A: Malignant melanoma during ustekinumab therapy of Crohn‘s disease. Inflamm Bowel Dis 2012; 18: E199–200 CrossRef MEDLINE
e28. Young L, Czarnecki D: The rapid onset of multiple squamous cell carcinomas in two patients commenced on ustekinumab as treatment of psoriasis. Australas J Dermatol 2012; 53: 57–60 CrossRef MEDLINE
e29. Gratton D, Szapary P, Goyal K, Fakharzadeh S, Germain V, Saltiel P: Reversible posterior leukoencephalopathy syndrome in a patient treated with ustekinumab: case report and review of the literature. Arch Dermatol 2011; 147: 1197–202 CrossRef MEDLINE
e30.Niehues T: Therapeutic monoclonal antibodies as immunomodulators and anti-cancer agents: development, evidence of efficacy, mechanisms of actions, adverse effects in antibody therapy. In: Imbach P, eds.: Antibody therapy, substitution – immunomodulation – monoclonal immunotherapy Springer Verlag 2018; 291–341 CrossRef